Aspirin IV Formulation via pH and Cosolvent Stabilization
Solution Overview
Problem
The development of a stable injectable form of aspirin has been hindered by its poor solubility and rapid hydrolytic degradation, making it difficult to create a commercially viable lyophilized or solution formulation for intravenous use, which is essential for immediate therapeutic action in conditions like acute coronary syndrome.
Innovation Solution
A liquid aspirin composition with a cosolvent mixture of organic solvent and water, specifically t-butyl alcohol and water, is used to enhance stability, allowing for the preparation of lyophilized aspirin with a shelf life of at least 2 years, and a kit is provided for reconstitution to achieve a pH near physiological levels for intravenous administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If aspirin is formulated as an injectable solution in aqueous medium, then rapid therapeutic action is achieved, but hydrolytic degradation occurs rapidly with half-life of about 6 days
Solution Approach 1:
The patent changes the pH parameter of the aqueous medium to approximately 8.5, which is significantly higher than the normal physiological pH. This parameter change reduces the hydrolytic degradation rate of aspirin while maintaining its solubility and therapeutic efficacy, thus resolving the contradiction between rapid action and stability.
Solution Approach 2:
The patent introduces an intermediary substance (a base such as sodium hydroxide or potassium hydroxide) to adjust and maintain the pH of the aqueous medium at approximately 8.5. This intermediary protects aspirin from rapid hydrolysis by creating a favorable chemical environment, enabling both rapid therapeutic action and improved stability.
2Stability of the object's composition
If aspirin is formulated as a lyophilized preparation, then storage stability is improved, but 10% potency loss occurs in about 1.3 hours under ambient conditions
Solution Approach 1:
The patent changes the pH parameter to approximately 8.5 before lyophilization, which stabilizes aspirin against hydrolytic degradation during the lyophilization process and subsequent storage. This parameter modification ensures that the lyophilized preparation maintains its potency without significant loss, achieving both storage stability and reliability.
3Quantity of substance
If aspirin solubility is increased by adjusting pH to 5.5 and above, then solubility increases to more than 100 mg/ml, but hydrolytic degradation rate remains high with half-life of about 6 days
Solution Approach 1:
The patent further increases the pH parameter from 5.5 to approximately 8.5, which simultaneously maintains high solubility of aspirin (more than 100 mg/ml) and significantly reduces the hydrolytic degradation rate. This extended pH adjustment resolves the contradiction between achieving high solubility and maintaining stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in a stable and effective intravenous aspirin formulation that maintains minimal degradation, enabling rapid and predictable therapeutic action for conditions such as acute coronary syndrome, with improved solubility and stability that overcomes previous formulation challenges.
Implementation Method 1
A liquid aspirin composition with a cosolvent mixture of organic solvent and water, specifically t-butyl alcohol and water, is used to enhance stability
Implementation Method 2
allowing for the preparation of lyophilized aspirin with a shelf life of at least 2 years
Data Source
AI summary
Improved, stable aspirin formulations for intravenous use are disclosed. Methods of lyophilizing the aspirin from bulk solutions as well as kits containing the lyophilized aspirin and methods of treatment using the same are also disclosed.



